HSBC Holdings’s Meridian Bioscience Inc VIVO Stock Holding History

HSBC Holdings’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-441,656	Closed	-$14.7M	–	3270
2022 Q4	$14.7M	Buy	441,656 +34,250	+8%	+$1.1M	0.02%	771
2022 Q3	$12.9M	Buy	407,406 +395,886	+3,437%	+$12.8M	0.02%	735
2022 Q2	$353K	Sell	11,520 -975	-8%	-$26.4K	﹤0.01%	2541
2022 Q1	$332K	Buy	+12,495	New	+$297K	﹤0.01%	2689
2021 Q1	–	Sell	-18,966	Closed	-$358K	–	3244
2020 Q4	$358K	Sell	18,966 -6,272	-25%	-$117K	﹤0.01%	2448
2020 Q3	$426K	Buy	+25,238	New	+$491K	﹤0.01%	2042
2019 Q1	–	Sell	-54,069	Closed	-$939K	–	2936
2018 Q4	$939K	Buy	+54,069	New	+$922K	﹤0.01%	1817

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HSBC Holdings's VIVO Position: Q1 2023 in Review

HSBC Holdings sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 441,656 shares — an estimated $14.7M sold.

HSBC Holdings first reported a position in VIVO in Q4 2018 and held it in 7 quarters. The position peaked at $14.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

HSBC Holdings reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
HSBC Holdings sold 441,656 Meridian Bioscience Inc shares in Q1 2023, an estimated $14.7M.
HSBC Holdings first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 7 quarters.
HSBC Holdings's Meridian Bioscience Inc position peaked at $14.7M in Q4 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on HSBC Holdings's 13F filing for Q1 2023, filed 15 May 2023.